Stockhead TV
Check out the latest Medtech news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts.
Aftermarket
What is amycretin? The new weight-loss pill that’s ‘twice as effective’ as Ozempic
News
ASX Rebalance: Tech in, lithium out of S&P/ASX 200 as uranium stocks enter S&P/ASX 300
Experts
Dr Boreham’s Crucible: Don’t have a heart attack, CSL’s profit-making ability is in the blood
Health & Biotech
Dr Boreham’s Crucible: ResMed holders breathe easy – those fat-busting needles have only hurt a little bit
Stockhead TV
What’s in store for 2024: Optiscan
Tech
Stock Insiders: Optiscan is expanding and the potential is enormous
Health & Biotech
Huge IPO interest and not lithium? LTR Pharma could be the next big thing on the ASX
Health & Biotech
Allegra’s game-changing Spinal Cage device awaits FDA nod, as ASX medical device stocks make inroads
Tech
Optiscan’s platform could address global pathologist shortage
News
Closing Bell: Friday takes a bite out of ASX, even as biotech and lithium small caps run amok
Tech
‘Take advantage of market consolidation’: EYE ready for proposed US Medicare changes
Health & Biotech
‘Diagnose on the spot’: Optiscan’s platform brings together surgeons and pathologists for better cancer outcomes
Health & Biotech
Curvebeam AI CEO says medical devices beat drugs to revenue, massive market in medical imaging
Health & Biotech
MDMA and magic mushrooms have arrived: Australia lets psychs find a new way for happy to fight sad
News
Rise and Shine: Everything you need to know about the day ahead
News
Top 10 at 10: Microcap biotech Imagion up 33pc after achieving enrolment target for Phase 1 trial
Experts
SUNDAY ROAST: The small caps that lit a fire under Stockhead’s experts this week
Health & Biotech
Stock Insiders: Nova Eye Medical surges 20pc after FDA clears glaucoma treatment
News
Rise and Shine: Everything you need to know before the ASX opens
Health & Biotech
Health Kick Podcast: Aussie Bio Tech Medlab is confident in highly anticipated Phase III trial
Health & Biotech
CardieX Raises $4.5 million as it gears up for dual US listing as CONNEQT Pulse awaits FDA Clearance
Stockhead TV
2023 Prepped and Primed: Opyl (ASX:OPL) with CEO, Michelle Gallaher
Experts
Tim Boreham’s 20 ASX stocks that are primed to run in 2023 – Part 2
Stockhead TV
Year in Review: Opyl (ASX:OPL) with CEO, Michelle Gallaher
Health & Biotech
Opyl’s TrialKey achieves major milestone with potential to improve clinical trial success rates
Experts
Innovation never sleeps: Franklin Templeton says watch these 5 big tech shifts this quarter
Health & Biotech
Opyl tips revenue growth from partnership with Consentic and its newly launched screening services
Investor Guides
Investor Guide: Health & Biotech FY2023
Stockhead TV
CAR-T therapies are leading the race to cure cancer
Health & Biotech
Opyl appoints news chairman as it eyes international growth
Health & Biotech
Opyl prepares to launch Opin into the global $4.7 billion clinical trial recruitment market
Escrow Watch
ASX Escrow Watch: Spring is in the air and so is the season for releasing shares
Health & Biotech
CardieX pumped up with insto support for $4.33 million raise – announces additional purchase plan for shareholders
News
ASX Small Caps Lunch Wrap: Who’s making an unlikely political tilt today?
Health & Biotech
Health Kick Podcast: How Osteopore is innovating in the area of bone and tissue regeneration
Health & Biotech
Stock Insiders: MGC Pharmaceuticals’ ‘golden blanket’ combines multiple elements for better patient efficacy
Stockhead TV
V-Con: Small Cap Showcase Part 2 – Finding strong companies in a weak market
Health & Biotech
Leading Aussie medtechs Osteopore and Singular Health reveal landmark deal
Experts
MoneyTalks: Get your portfolio in rude health with these 3 ASX life science stocks
Tech
Best results yet: Audeara smashes quarterly sales records, up 175% PCP
Tech
Global retail deal with Amplifon has Audeara shouting from on top of the world
Health & Biotech
Opyl joins forces with two key patient advocate groups
Health & Biotech
Cast your eyes over these 15 weird and wonderful biotech stocks we found on the ASX
Experts
ScoPo’s Powerplays: ASX health stocks offer bargains galore during tax time sell down
Experts
ScoPo’s Powerplays: Who stands out in the enterprise imaging sector?
Health & Biotech
Primed for growth: Audeara increases sales channels by 20% by partnering with optometry giant Specsavers
Health & Biotech
Stock Insiders: NGS are reaching new heights with a clinically tested nutritional supplement
Load More